Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $291.00 at Citigroup

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective boosted by Citigroup from $227.00 to $291.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on ALNY. Barclays increased their price target on Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the company an overweight rating in a report on Tuesday. William Blair reissued an outperform rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. HC Wainwright restated a buy rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday. SVB Leerink upped their price objective on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a market perform rating in a research note on Tuesday. Finally, Bank of America upped their price objective on Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the stock a buy rating in a research note on Tuesday. Eight research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of $245.14.

Alnylam Pharmaceuticals Trading Up 0.7 %

ALNY stock opened at $247.00 on Tuesday. The stock has a market capitalization of $31.24 billion, a PE ratio of -92.16 and a beta of 0.30. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $252.87. The stock’s 50 day simple moving average is $157.89 and its 200 day simple moving average is $164.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. The business’s revenue was up 54.8% compared to the same quarter last year. During the same period last year, the company posted ($1.40) earnings per share. On average, research analysts predict that Alnylam Pharmaceuticals will post -3.75 earnings per share for the current year.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 8,301 shares of the stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $1,917,447.99. Following the completion of the transaction, the chief executive officer now owns 80,534 shares of the company’s stock, valued at approximately $18,602,548.66. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the firm’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the sale, the director now owns 136 shares of the company’s stock, valued at $30,013.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 8,301 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the completion of the sale, the chief executive officer now directly owns 80,534 shares of the company’s stock, valued at approximately $18,602,548.66. The disclosure for this sale can be found here. Insiders sold a total of 67,357 shares of company stock worth $13,436,711 over the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Harbor Capital Advisors Inc. raised its stake in shares of Alnylam Pharmaceuticals by 1.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock valued at $562,000 after acquiring an additional 51 shares in the last quarter. EP Wealth Advisors LLC increased its holdings in Alnylam Pharmaceuticals by 6.4% during the third quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 71 shares during the period. Commerce Bank increased its holdings in Alnylam Pharmaceuticals by 1.7% during the fourth quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company’s stock valued at $896,000 after buying an additional 77 shares during the period. Envestnet Portfolio Solutions Inc. grew its holdings in Alnylam Pharmaceuticals by 7.0% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 89 shares during the last quarter. Finally, Metis Global Partners LLC grew its holdings in Alnylam Pharmaceuticals by 2.2% in the fourth quarter. Metis Global Partners LLC now owns 4,382 shares of the biopharmaceutical company’s stock worth $839,000 after purchasing an additional 94 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.